Zacks Research Weighs in on Corcept Therapeutics Incorporated’s Q3 2025 Earnings (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research raised their Q3 2025 earnings per share estimates for Corcept Therapeutics in a report issued on Wednesday, April 17th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings per share of $0.26 for the quarter, up from their previous estimate of $0.25. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.92 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.40 EPS, FY2025 earnings at $1.14 EPS and Q1 2026 earnings at $0.39 EPS.

Several other equities analysts have also commented on CORT. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. HC Wainwright cut their target price on Corcept Therapeutics from $34.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, January 2nd. Finally, Truist Financial raised their price target on Corcept Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics currently has an average rating of “Buy” and a consensus target price of $37.30.

Corcept Therapeutics Trading Down 1.7 %

NASDAQ:CORT opened at $23.00 on Thursday. The company has a market cap of $2.38 billion, a price-to-earnings ratio of 24.21 and a beta of 0.48. Corcept Therapeutics has a twelve month low of $20.87 and a twelve month high of $34.28. The stock has a fifty day simple moving average of $23.92 and a 200-day simple moving average of $25.53.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Thursday, February 15th. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.03. Corcept Therapeutics had a return on equity of 21.98% and a net margin of 21.86%. The business had revenue of $135.41 million during the quarter, compared to the consensus estimate of $129.27 million. During the same period last year, the company earned $0.14 earnings per share. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in Corcept Therapeutics by 2.5% during the 1st quarter. BlackRock Inc. now owns 15,424,767 shares of the biotechnology company’s stock worth $347,366,000 after acquiring an additional 376,774 shares in the last quarter. Vanguard Group Inc. lifted its stake in Corcept Therapeutics by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 10,332,077 shares of the biotechnology company’s stock worth $264,915,000 after acquiring an additional 458,414 shares in the last quarter. Federated Hermes Inc. lifted its stake in Corcept Therapeutics by 2.5% during the 1st quarter. Federated Hermes Inc. now owns 4,740,420 shares of the biotechnology company’s stock worth $106,754,000 after acquiring an additional 114,571 shares in the last quarter. Parallel Advisors LLC increased its holdings in Corcept Therapeutics by 1.2% during the 4th quarter. Parallel Advisors LLC now owns 3,768,245 shares of the biotechnology company’s stock worth $122,393,000 after purchasing an additional 44,762 shares during the period. Finally, State Street Corp increased its holdings in Corcept Therapeutics by 2.6% during the 2nd quarter. State Street Corp now owns 3,499,446 shares of the biotechnology company’s stock worth $83,217,000 after purchasing an additional 89,888 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $22.00, for a total value of $48,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $22.00, for a total value of $48,400.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Sean Maduck sold 27,068 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.97, for a total value of $702,955.96. Following the completion of the transaction, the insider now directly owns 74,455 shares in the company, valued at approximately $1,933,596.35. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 83,783 shares of company stock worth $2,118,996. 18.60% of the stock is owned by corporate insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.